Evolution in the prescription of the therapy combined with ICS-LABA in COPD: TRACE STUDY

Introduction: Several reports inform about the over prescription of ICS for COPD. The availability of double bronchodilation may have changed this trend. The objective of this communication is to monitor recent trends in ICS prescription and assess the impact of the GOLD 2017 classification on it. Method: TRACE (Time-based Register and Analysis of COPD Endpoints) is an ongoing observational prospective cohort study based in data of the real life whose objective is the study of the temporal progression of common parameters of clinical practice. It began in January 2012 through annual visits. For this analysis we performed a descriptive study of the evolution in ICS-LABA prescription both in the overall cohort as divided by GOLD groups (2011-2017). Results: The cohort includes 391 patients with COPD (87% men, 29.7% active smokers, age 68 ± 10 years, FEV1 53.7 ± 17.3%). The prescription of ICS-LABA on the recruiting visit was 62.1% (GOLD2011 A 43.5% - GOLD2011 D 82.6%, p Conclusion: The prescription of the ICS-LABA combination is drastically declining in the management of stable situation COPD, without an increase of the acute episodes.